Enteral Nutrition Clinical Trial
— AlgiNGOfficial title:
Gastric, Biochemical, Endocrine and Appetitive Responses to an Enterally Fed Alginate-containing Feed, Compared With an Alginate Free Feed
Verified date | September 2022 |
Source | University of Nottingham |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
When patients cannot eat and drink enough a tube can be placed through their nostril, down the back of their throat into their stomach and used to give their nutrition as a liquid feed. One of the commonest problems when using this tube is regurgitation of feed up from the stomach (gastro- oesophageal reflux (GOR)), or liquid stools (diarrhoea). This can cause the patient discomfort, a higher risk of getting a skin or chest infection, and increase the risk that the feed is stopped. The investigators intend to investigate, in twelve healthy young men, whether adding a form of dietary fibre (alginate) to the feed could reduce these symptoms (diarrhoea and GOR), hence ensuring patients are properly nourished and recover as quickly as possible from their illness, Each volunteer will come to the lab twice and will have a tube inserted into the stomach via the nose so that they can be given both feeds. Each time, the investigators will take repeated pictures of how the feed is passing through their gut using a non invasive technique called 'magnetic resonance imaging' (MRI), take blood samples to see how quickly the nutrition is absorbed into the blood, and measure how hungry they feel
Status | Completed |
Enrollment | 12 |
Est. completion date | March 30, 2020 |
Est. primary completion date | March 30, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Non- smoking (non- vaping) males - aged 18- 45 years - body mass index (BMI) of 18.5-24.5kg/ m2 or a BMI of 24.5- 26kg/ m2 - a waist circumference of less than 94 cm. - ability to give informed consent Exclusion Criteria: - A history of an acute illness, lasting more than a week, in the last six weeks; - taking any medications for gastrointestinal disorders, including acid suppressants or anti-spasmodics, - taking anti-depressants or symptoms of clinical depression (defined by a score >10 on the Beck Depression Inventory) - taking medication for diabetes or having diabetes - a history of substance abuse in the last six months; - having any factors that preclude safe MRI; - a history of gastrointestinal disorders, including Gastro Oesophgeal Reflux Disease, Irritable Bowel Syndrome, active peptic ulcer disease; having diabetes; - previous surgery to the gastrointestinal or biliary systems; - having characteristics of those with an eating disorders (defined by a score of more than 20 on the Eating Attitudes Test (EAT-26)); - having an allergy or intolerance to the ingredients in the enteral feeds, or the cheese and tomato pasta meal |
Country | Name | City | State |
---|---|---|---|
United Kingdom | The University of Nottingham | Nottingham | Nottinghamshire |
Lead Sponsor | Collaborator |
---|---|
University of Nottingham | Kaneka Corporation |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Small bowel water response to feeding | Area under the curve for small bowel water measured by MRI over four hours from baseline. | After four hours from baseline | |
Secondary | Gastric volume relative to baseline | Area under the curve for gastric volume relative to baseline, measured by MRI for four hours from baseline. | After four hours from baseline | |
Secondary | Mean post feeding gastric emptying rate | Mean gastric emptying rate calculated from MRI images of gastric volume obtained over four hours from baseline. | Over four hours from baseline. | |
Secondary | Superior mesenteric blood flow | Mean superior mesenteric blood flow calculated from measurements over four hours from baseline. | Over four hours from baseline. | |
Secondary | Incremental area under the curve for arterialised whole blood glucose | Incremental area under the curve for arterialised whole blood glucose will be calculated using samples collected at 10 minute intervals between baseline and four hours. | Over four hours post baseline | |
Secondary | Incremental area under the curve for insulin | Incremental area under the curve for insulin will be calculated using samples collected at 20 minute intervals between baseline and four hours. | Over four hours from baseline | |
Secondary | Incremental area under the curve for PYY (Peptide YY) | Incremental area under the curve for PYY will be calculated using samples collected at 20 minute intervals between baseline and four hours. | Over four hours from baseline | |
Secondary | Incremental area under the curve for Gastric Inhibitory Polypeptide | Incremental area under the curve for GIP will be calculated using samples collected at 20 minute intervals between baseline and four hours. | Over four hours from baseline | |
Secondary | Incremental area under the curve for Glucagon-like peptide 1 (GLP- 1) | Incremental area under the curve for GLP-1 will be calculated using samples collected at 20 minute intervals between baseline and four hours. | Over four hours from baseline | |
Secondary | Incremental area under the curve for Ghrelin | Incremental area under the curve for Ghrelin will be calculated using samples collected at 20 minute intervals between baseline and four hours. | Over four hours from baseline | |
Secondary | Incremental area under the curve for composite satiety score | Composite satiety score will be calculated using 100mm visual analogue score ratings of satiety, fullness, hunger and prospective food consumption collected every 30 minutes between baseline and four hours. | Over four hours from baseline | |
Secondary | Weight of consumption of a pasta meal four hours and thirty minutes after baseline. | Weight of pasta consumed from a bowl refilled prior to being empty until participants feel comfortably full. | Four hours and thirty minutes post baseline. | |
Secondary | Change in Faecal pH from baseline | The difference between faecal pH pre feeding and post feeding will be compared. | Comparison between sample obtained immediately before the enteral feeding day and samples obtained during the three days following the enteral feeding day. | |
Secondary | Faecal consistency | Rating of consistency of faecal sample will be compared with rating of consistency post enteral feeding day. | Comparison between sample obtained immediately before the enteral feeding day and samples obtained during the three days following the enteral feeding day. | |
Secondary | Incremental area under the curve for gastric symptom scores rated using visual analogue scores. | Incremental area under the curve for gastric symptoms will be calculated using 100mm visual analogue score ratings obtained every half hour between baseline and four hours. | Over four hours from baseline. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02913677 -
Prolonged Minimal Enteral Nutrition Versus Slowly Advancing Enteral Nutrition in Very Low Birth Weight Infants:
|
N/A | |
Not yet recruiting |
NCT00916591 -
Prokinetic Drugs and Enteral Nutrition
|
N/A | |
Completed |
NCT01025167 -
The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and Chemotherapy in Cancer Patients
|
N/A | |
Not yet recruiting |
NCT05900323 -
Enteral Nutrition Guidelines and Patients' Outcomes
|
N/A | |
Completed |
NCT03153397 -
Effect of Prebiotic Fiber- Enriched (scFOS) Enteral Feeding on the Microbiome in Neurological Injury Trauma Patients (PreFEED Microbiome Trial)
|
N/A | |
Completed |
NCT02353689 -
The Effect of FODMAP Content in Tube Feeding Formula on Feeding Intolerance and Nutritional Status Improvement
|
Phase 2/Phase 3 | |
Terminated |
NCT00564655 -
Regional Anesthesia Block of the Transversus Abdominis Plane in Children Undergoing Gastric Tube Insertion
|
Phase 3 | |
Completed |
NCT06134674 -
Early Versus Delayed Enteral Nutrition in Critically Ill Adults With COVID-19
|
||
Recruiting |
NCT03791866 -
The Th9/IL-9 and Early Enteral Nutrition in Sepsis
|
N/A | |
Enrolling by invitation |
NCT06161350 -
The Multi-disciplinary Approach of Children With Feeding Difficulties and Tube Feeding in UZB Between 2000 and 2021
|
||
Active, not recruiting |
NCT02724631 -
TubeClear® Evaluation in Pediatric Patients (Phase I)
|
N/A | |
Completed |
NCT01988792 -
Human Milk Fortification in Very Low Birth Neonates
|
N/A | |
Completed |
NCT00600678 -
Gastric Emptying Study After Administration of a High Caloric Sip Feed
|
N/A | |
Completed |
NCT02998931 -
Trial of Enteral Glutamine on Clinical Outcomes in Critically Ill Patients
|
Phase 3 | |
Not yet recruiting |
NCT06411873 -
The Effect of High Protein Enteral Nutrition on Critically Ill Postoperative Children
|
N/A | |
Recruiting |
NCT03176875 -
Comparison of Partial and Exclusive Enteral Nutrition in the Treatment of Active Childhood-onset Crohn's Disease
|
N/A | |
Completed |
NCT02779335 -
Enteral Formula Tolerance in Pediatric Patients
|
N/A | |
Completed |
NCT05411848 -
2kcal Tube Feed Study
|
N/A | |
Completed |
NCT04868318 -
The Impact of Intervention With High-protein Enteral Formula in SICU.
|
N/A | |
Withdrawn |
NCT04601571 -
Confirming Feeding Tube Position Using CORTRAK
|
N/A |